Q32 Bio (NASDAQ:QTTB) vs. Genelux (NASDAQ:GNLX) Head-To-Head Survey

Genelux (NASDAQ:GNLX) and Q32 Bio (NASDAQ:QTTB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Insider and Institutional Ownership

37.3% of Genelux shares are owned by institutional investors. Comparatively, 31.3% of Q32 Bio shares are owned by institutional investors. 7.5% of Genelux shares are owned by insiders. Comparatively, 34.5% of Q32 Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Genelux and Q32 Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-205.85%	-138.79%
Q32 Bio	N/A	31.69%	25.50%

Earnings & Valuation

This table compares Genelux and Q32 Bio”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$10,000.00	9,364.68	-$32.15 million	($0.86)	-2.41
Q32 Bio	$53.74 million	5.17	$29.82 million	$3.34	2.80

Q32 Bio has higher revenue and earnings than Genelux. Genelux is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Genelux has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, Q32 Bio has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for Genelux and Q32 Bio, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1	0	2	1	2.75
Q32 Bio	0	2	6	1	2.89

Genelux currently has a consensus target price of $20.00, suggesting a potential upside of 866.18%. Q32 Bio has a consensus target price of $32.17, suggesting a potential upside of 244.40%. Given Genelux’s higher possible upside, research analysts plainly believe Genelux is more favorable than Q32 Bio.

Summary

Q32 Bio beats Genelux on 9 of the 13 factors compared between the two stocks.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

About Q32 Bio

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.